StockData

OrthoPediatrics vs Xtant Medical

KIDS and XTNT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KIDS and XTNT compare

OrthoPediatrics is the larger company, worth 28 times as much as Xtant Medical ($820M against $28.8M).

OrthoPediatrics grew revenue faster over the last twelve months (16.1% versus −14.3% for Xtant Medical).

Xtant Medical keeps more of each dollar of sales as profit, with a net margin of −10.2% compared with −12.8% at OrthoPediatrics.

OrthoPediatrics scores higher on the StockData Score (11 against 9 for Xtant Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKIDSXTNT
Size and price
Market cap$820M$28.8M
Share price$31.41$0.205
Change, 1 year88.0%−68.5%
Change, 5 years−46.0%−73.8%
Beta (5Y)0.690.10
Employees602151
StockData Score
Total score11 (better)9
Valuation score23 (better)
Growth score4 (better)1
Performance score3 (better)2
Health score23 (better)
Dividend score00
Valuation
P/S3.1×0.3× (better)
P/B2.4×0.7× (better)
P/FCF258×–
FCF yield0.39% (better)−2.4%
Fair value$34.15$1.04
Margin of safety8.0%80.3% (better)
Growth
Revenue growth (TTM)16.1% (better)−14.3%
Revenue growth, 5Y average27.2% (better)20.2%
Profitability
Gross margin73.8% (better)59.4%
Operating margin−9.4% (better)−9.6%
Net margin−12.8%−10.2% (better)
FCF margin1.2% (better)−0.64%
Return on equity−9.8% (better)−25.2%
Return on invested capital−5.0% (better)−15.8%
Financial health
Debt / equity0.300.28 (better)
Interest coverage−2.7× (better)−3.8×
Current ratio4.55 (better)2.16
Altman Z-score2.90 (better)−2.79
Piotroski F-score48 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions64.3%106%
Held by insiders30.2%–
Insider net buying, 12 months−$47.8M–
Short interest, % of float4.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.